HeartWare dives on big Q1 sales, earnings misses
Shares prices for HeartWare International (NSDQ:HTWR) plunged this morning after the implantable heart pump maker posted 1st-quarter earnings that badly missed expectations on Wall Street. Framingham, Mass.-based HeartWare reported that losses widened 20.1% to -$17.5 million, or -$1 per share, on a -21.3% revenue slide to $55.1 million. Adjusted to exclude 1-time items, losses per share were -95¢, -16¢ off the forecast on The Street, where analysts were looking for sales of $59.9 million. “In the 1st quarter, our international revenue performance was impacted by competitive dynamics in Germany, as well as lower implant volumes in certain other international markets,” president &CEO Doug Godshall said in prepared remarks. “In the U.S., the bridge-to-transplant segment of the market for which the HVAD system is approved, showed softness resulting from a slowdown in the volume of patients eligible for bridge-to-transplant procedures at the start of the year and an evolving trend toward destination therapy due to ease of reimbursement. Our 1st-quarter financial performance and the overall market dynamics reinforce the importance of our work toward securing a DT indication in the U.S. and focusing our energies upon the continued enhancement of our technologies. “Despite 1st-quarter trends, the HVAD system remains the most versatile pump, utilized in the widest range of patients, among currently available ventricular as...
The objective of this report was to summarize current knowledge of CC, squamous intraepithelial lesions, and human papillomavirus (HPV) infection in non-HIV immunocompromised women to determine best practices for CC surveillance in this population and provide recommendations for screening. We evaluated those with solid organ transplant, hematopoietic stem cell transplant, and a number of autoimmune diseases. A panel of health care professionals involved in CC research and care was assembled to review and discuss existing literature on the subject and come to conclusions about screening based on available evidence and expe...
ConclusionsCurrent psychosocial assessment practices in LVAD programs vary widely and often yield non-standardized, non-comparable data that may lead to variations in care and limit generation of an evidence base for decision making regarding psychosocial eligibility for LVAD implantation.
Frailty is common in adults with end-stage lung disease and is associated with death before and after lung transplantation. We aimed to determine whether frailty changes from before to after lung transplant.
END-STAGE HEART FAILURE (HF) results from a myriad of etiologies and represents a major financial and healthcare burden.1 Since 1983, nearly 150,000 pediatric and adult heart transplants have been reported to the International Society for Heart and Lung Transplantation (ISHLT) Registry, with medical advancements in perioperative care resulting in improved patient outcomes over time.2 This paper aims to assess outcomes within the field of heart transplantation. The authors will focus on historical context, current demographics, indications, and contraindications for transplantation.
Right-sided heart failure develops in lung transplantation candidates on prolonged peripheral extracorporeal membrane oxygenation support and is a major determinant of mortality. The use of central venoarterial extracorporeal membrane oxygenation for bridging of right-sided heart failure to lung transplantation was evaluated.
This study provides a possible reason why genes carrying health risks have persisted in human populations. The second found evidence for multiple variants in genes related to ageing that exhibited antagonistic pleiotropic effects. They found higher risk allele frequencies with large effect sizes for late-onset diseases (relative to early-onset diseases) and an excess of variants with antagonistic effects expressed through early and late life diseases. There also exists other recent tangible evidence of antagonistic pleiotropy in specific human genes. The SPATA31 gene has been found under strong positive genomic sele...
We have applied cutting-edge mass cytometry (MC) technology to serial bronchoalveolar lavage (BAL) cells obtained from lung transplant recipients (LTRs) and have used it to compare the cellular composition of the BAL compartment in patients who remain stable or go on to develop lung allograft dysfunction (LAD), defined here as a drop, from any cause, in the forced expiratory volume in 1 second of 20% from the best post-transplant baseline value.
We examined the ratio of regulatory T cells (Tregs, which express Foxp3) to T effector cells (Teff) in TBBx as a predictor of outcome.
Long-term survival after lung transplantation (LTx) is hampered by chronic lung allograft dysfunction, with bronchiolitis obliterans syndrome (BOS) as its most common phenotype. Bronchiectasis (BRECT), hyperinflation and airtrapping are considered the key features of BOS on chest CT. We investigated whether chest CT and key features have prognostic value at BOS diagnosis in patients with established BOS after LTx.
Chronic Allograft Dysfunction (CLAD) with Bronchiolitis obliterans (BOS) phenotype is a major limitation for long term survival after lung transplantation (LT). Predictive biomarkers for BOS are unavailable. Purpose of our study was to establish a tractable system to evaluate the effects of pre-transplant antibodies to self-antigens (AutoAbs) and to examine specific patterns that correlate with BOS.